



Press release from Emotra AB (publ)
Göteborg, September 30, 2014

Emotra signs collaborative agreements with researchers

Emotra has signed collaborative agreements with two Swedish researchers. Both of these researchers' doctor's theses were based on studies of electro-dermal reactivity and autonomous functions in the nervous system. Our aim with these agreements is to reinforce and expand Emotra's scientific base as well as meet increasing demand for analyses of EDOR tests. Collaboration with these researchers has been enabled by, among other things, our newly developed software for facilitating analysis efforts.

So far, Emotra has been completely dependent on the method's inventor, Lars-Håkan Thorell, for analysis of the EDOR test results from patient evaluations and for further development of the method. No one else has possessed sufficiently deep knowledge to be able to spur further development of the method, or understood the technology well enough to be able to analyse test data. The Company has employed a test analyst who assists Mr Thorell in these efforts. From a long-term point of view, this is an unsustainable situation for the Company and puts Emotra at risk.

With these agreements, the Company has now tied two experienced and skilful researchers that the Company has enjoyed good relations with for several years. We have signed long-term contracts which ensure that all know-how about the method remains Emotra's property. In the near future, these researchers will receive further training on the method before moving on to analysing test results during a period. These test results will also be analysed by Emotra to quality-assure their training.

Since these researchers are already knowledgeable in the subject area, the Company is counting on their being up and running in a relatively short time. As soon as they are fully trained and we have quality-assured their analysis results, they will assist Emotra by independently analysing our test results. Through the development of software that significantly facilitates analysis efforts and by assigning more independently working researchers, the Company will be able to meet an increase in analysis demand.

"Emotra is in the middle of a very dynamic phase. An extensive, multi-centre clinical study is presently being conducted in Europe. By tying these researchers to the Company, we are working to secure our long-term competence needs. We have secured two young researchers that can contribute to our further development of the EDOR method and strengthen our collaborative efforts with researchers and clinics around the world. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe," says CEO Claes Holmberg.

For further information, please contact:

Claes Holmberg, CEO
Telephone: +47 708 25 45 47
E-mail: claes@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.